NCT02330796View on ClinicalTrials.gov

Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout

PHASE2CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

November 30, 2015

Study Completion Date

November 30, 2015

Conditions
Gout
Interventions
DRUG

Bucillamine

Bucillamine Tablets

DRUG

Colchicine

Trial Locations (3)

76015

Texas Physicians Research Medical Group, Arlington

78215

Sun Research Institute, San Antonio

94582

West Coast Research, San Roman

All Listed Sponsors
lead

Revive Therapeutics, Ltd.

INDUSTRY

NCT02330796 - Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe Gout | Biotech Hunter | Biotech Hunter